Tengion, Inc. is an US development-stage regenerative medicine company founded in 2003 with financing from J&J Development Corporation, HealthCap and Oak Investment Partners, which is headquartered in Winston-Salem, North Carolina.[1] Its goals are discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues, to address unmet medical needs in urologic, renal, gastrointestinal, and vascular diseases and disorders. The company creates these human neo-organs from a patient’s own cells or autologous cells, in conjunction with its Organ Regeneration Platform.
Tengion declared Chapter 7 bankruptcy in December 2014, and liquidated its assets.[2] In March 2015 its assets, including tissue engineering samples, were bought back by its creditors and former executives in March 2015. The purchase was expedited.[3] The new owners then formed Winston-Salem based RegenMedTX.[4]